<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

Organization Authors

Co-Authors

Voroneanu, Luminita

Siriopol, Dimitrie

Dumea, Raluca

Badarau, Silvia

Afşar, Barış

Gavrilovici, Cristina

Covic, Adrian

Date

Language

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background : In the last decade, despite constant investigation, no current single treatment has been able to decrease the incidence of diabetic nephropathy and to significantly reduce progression of diabetic CKD. Methods : Patients with type 2 diabetes mellitus and proteinuria (> 0.5 g/day) after a screening and treatment optimization phase were randomly assigned to receive silymarin or placebo. The primary outcome was a composite outcome: mortality, decline of eGFR > 50% and renal replacement therapy. Secondary outcomes were a composite renal outcome (defined as a decline of eGFR >= 50% or ESRD) and also to test the effect of silymarin on the change in eGFR and proteinuria. We also assessed the adverse effects (hospitalizations, headache or gastrointestinal symptoms) during the study. Results : One hundred and two patients were included in the study. There were no significant differences between the two study groups regarding the primary and renal outcomes (HR 0.62, 95% CI 0.3-1.2, p = 0.15; HR 0.56, 95% CI 0.26-1.24, p = 0.16, respectively). At study end, eGFR declined significantly in both arms (p < 0.001), irrespective of the treatment group allocation, and there were no significant changes in proteinuria. There was a significant difference in hospitalizations rates between the two study groups (0.61, 95% CI 0.44-0.85). Conclusions : Silymarin did not show a significant reduction in the primary and secondary outcomes. Importantly, silymarin treatment was associated with a significant reduction in the hospitalization rate.

Source

Publisher

Springer

Citation

item.page.haspartof

Source

International Urology and Nephrology

item.page.ispartofseries

item.page.edition

DOI

10.1007/s11255-017-1697-5

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Item type:Goal, Access status: Open Access ,
03 - Good Health and Well-being
Over the last 15 years, the number of childhood deaths has been cut in half. This proves that it is possible to win the fight against almost every disease. Still, we are spending an astonishing amount of money and resources on treating illnesses that are surprisingly easy to prevent. The new goal for worldwide Good Health promotes healthy lifestyles, preventive measures and modern, efficient healthcare for everyone.
Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators